Indonesia Pharma Serialization Compliance: What Exporters Must Know

Indonesia is moving decisively toward full pharmaceutical traceability, and for exporters, it’s time to act.

With the Badan Pengawas Obat dan Makanan (BPOM) rolling out BPOM Track and Trace regulations through its TTAC system, compliance is now essential for all products entering the Indonesian market.

This shift strengthens Indonesia’s pharma serialization and ensures safe and transparent drug supply across borders.

Understanding Indonesia’s Regulatory Roadmap

Under BPOM’s Track & Trace Anti-Counterfeit (TTAC) framework, the regulation aims to strengthen patient safety and prevent counterfeit medicines through serialization and digital monitoring.

Implementation timeline:

• Since December 2023: All pharmaceuticals and health products, including prescription, OTC, and traditional medicines, must display a 2D barcode (QR code) for identification.
• By December 2025: Serialization at the unit level becomes mandatory for high-risk products such as narcotics and psychotropics. The 2D GS1 DataMatrix must carry GTIN, batch number, expiry, and unique serial code.
• By December 2027: All prescription (hard) drugs must be serialized, aggregated, and reported to BPOM’s TTAC system.

While enforcement will phase in gradually, exporters should not underestimate the technical preparation required.

Serialization and aggregation impact every layer, from packaging equipment to enterprise data systems.

What It Means for Exporters

Non-compliance can delay customs clearance or block imports completely.

To safeguard exports, especially in the context of pharmaceutical export compliance in India and Indonesia, manufacturers must:

• Upgrade production lines for serialization and aggregation
• Use GS1 DataMatrix serialization solutions for barcodes and data structure
• Enable secure reporting to BPOM’s TTAC platform
• Maintain validated, tamper-proof manufacturing and logistics records

Those who invest early will avoid disruption and build stronger credibility with regulators and distribution partners.

How Jekson Vision Supports Exporters

Jekson Vision is a global leader in Track & Trace solutions, offering serialization and aggregation systems for regulatory compliance across multiple markets, including Indonesia, the EU, the US, and Africa.

Our in-house expertise covers L1 to L5 Track and Trace systems Jekson Vision, for complete compliance in one integrated setup:

• L1 Device Level: Serialization printers, scanners, vision systems
• L2 Line Level: Aggregation, line control, real-time inspection
• L3 Site Level: Centralized management across packaging lines
• L4 Enterprise Level: Data aggregation, reporting, ERP/MES integration
• L5 Government / Regulatory Level: Reporting to national systems like BPOM TTAC

This unified system removes the complexity of multiple vendors and accelerates compliance timelines.

Be Compliant. Be Ready. Be Ahead.

With Indonesia’s serialization deadlines approaching, now is the time to future-proof your operations.

Jekson Vision ensures seamless Track & Trace readiness with reliable, scalable, fully in-house solutions.

To know more, write to us: marketing@jeksonvision.com

FAQs: Indonesia Pharma Track & Trace

Q1: What is the BPOM Track & Trace regulation in Indonesia?

BPOM mandates 2D barcode serialization and aggregation to monitor all medicines through its TTAC system, ensuring supply-chain transparency and anti-counterfeit protection.

Q2: Who must comply with these regulations?

All pharmaceutical manufacturers and exporters supplying products to Indonesia, including Indian companies, must follow the serialization and reporting rules.

Q3: How can Jekson Vision help?

Jekson Vision provides complete Track & Trace solutions, hardware, and software, from Level 1 to Level 5, developed fully in-house to ensure seamless Indonesia pharma serialization compliance.